In this regard, proclivity towards pancreatic cancer that is likely to be caused by CDKN2A mutations [6-8], particularly among affected carriers of the R87P-p16 mutation, should be explored for early diagnosis/prognosis and intervention of pancreatic cancer. This evidence concerns the gene CDKN2A and pancreatic neoplasm.